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Death or Arrhythmic Events in Patients
With Primary Prevention ICDsIfy Mordi, MBCHB,* Pardeep S. Jhund, MB, PHD,* Roy S. Gardner, MD,y John Payne, MD,y
David Carrick, MBCHB,* Colin Berry, MD, PHD,*y Nikolaos Tzemos, MD*y
Glasgow and Clydebank, United KingdomOBJECTIVES The aim of this study was to investigate whether late gadolinium enhancement (LGE)
magnetic resonance imaging or N-terminal pro–B-type natriuretic peptide (NT-proBNP) could identify
patients with a low risk of death or use of implantable cardioverter-deﬁbrillator (ICD) in patients receiving
a primary prevention ICD.
BACKGROUND ICDs reducemortality inpatientswithheart failure (HF), although two-thirdsmaynever
use their device. Current risk stratiﬁcation, basedonNewYorkHeart Association functional class and left ven-
tricular ejection fraction, still leads to implantation of ICDs in patients who may never need their device.
METHODS We examined 157 patients with HF (61 with ischemic cardiomyopathy and 96 with
dilated cardiomyopathy; mean age 50.5 years; 78% male) who underwent primary prevention deﬁbril-
lator implantation. Presence and volume of LGE was measured before device implantation, and serum
NT-proBNP level was measured before ICD implantation. The combined primary endpoint was cardiovas-
cular death or appropriate ICD therapy (either appropriate shock or antitachycardia pacing).
RESULTS The primary outcome occurred in 32 patients (20.4%) over a median follow-up period of
915 days. Percentage of LGE (hazard ratio [HR]: per 1% increase: 1.06; 95% conﬁdence interval [CI]:
1.04 to 1.09; p < 0.001) and (ln) NT-proBNP (HR: 1.44; 95% CI: 1.04 to 1.98; p ¼ 0.027) were predictors
of death or appropriate ICD activation and remained signiﬁcant when entered into multivariable analysis.
When the cohort was stratiﬁed into tertiles based on LGE percentage and NT-proBNP, we were able to
identify a low-risk group (event rate 3% per year, compared with the intermediate- and high-risk groups
[6% and 10% per year, respectively]).
CONCLUSIONS Both percentage of LGE and NT-proBNP were associated with higher risk of death
or appropriate ICD activation. The use of these markers in combination may be useful in identifying in-
dividuals most likely to beneﬁt from this costly intervention, and more speciﬁcally, in the identiﬁcation of
a group at lower risk in whom ICD implantation may be deferred. (J Am Coll Cardiol Img 2014;7:561–9)
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CRT-D = cardiac
resynchronization therapy
(device with) deﬁbrillator
DCM = dilated cardiomyop
HF = heart failure
ICD = implantable
cardioverter-deﬁbrillator
ICM = ischemic cardiomyo
LGE = late gadolinium
enhancement
NT-proBNP = N-terminal
pro–B-type natriuretic pep
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562mplantable cardioverter-deﬁbrillators (ICDs) and made using either computed tomography (CT)
cardiac resynchronization therapy devices with a
deﬁbrillator function (CRT-Ds) have been
shown to reduce mortality when implanted to
prevent death in patients with heart failure (HF)
who have not had a prior cardiac arrest (i.e., a pri-
mary prevention device) (1,2). The average annual
rate of appropriate shocks in clinical trials is only
5.1%, and as many as two-thirds of patients may
never use their ICD after implantation (2–4).
Therefore, methods to improve the identiﬁcation of
individuals who may not be likely to beneﬁt from
ICD implantation meeting conventional criteria
such as New York Heart Association (NYHA)
functional class II to IV and reduced ejection frac-
tion are needed.
Late gadolinium enhancement (LGE) by cardiac
magnetic resonance (CMR) has been proposed as a
potential marker of risk identifying individuals mostathy
pathy
tidelikely to beneﬁt from an ICD. The pres-
ence of LGE is associated with a higher
risk of all-cause mortality, sudden cardiac
death, appropriate ICD activation, and
admissions for heart failure in patients with
HF with both ischemic cardiomyopathy
(ICM) and dilated cardiomyopathy
(DCM) (5–11). However, LGE quanti-
ﬁcation has a number of limitations;
furthermore, not all patients are able to
undergo CMR due to relative or absolute
contraindications or due to a contraindi-
cation to the administration of gadolinium.
In contrast, B-type natriuretic peptide
(BNP) and N-terminal pro-BNP (NT-
proBNP) are easily measured and have been
explored as a potential marker of risk in those
receiving a primary prevention ICD and as pre-
dictors of sudden death in patients with HF
(12–14). We assessed the association between LGE
and NT-proBNP and death or appropriate ICD
activation in individuals undergoing implantation
of a primary prevention ICD, and speciﬁcally,
hypothesized that the 2 markers may be combined
to predict a group of patients who may be at low risk
of ventricular arrhythmia and ICD activation.
METHODS
Patient selection. We prospectively evaluated 157
consecutive patients referred to our tertiary center
for implantation of primary prevention ICD or
CRT-D between January 2008 and December
2010. Patients with both ICM and nonischemic
DCM were included. The diagnosis of ICM wascoronary angiography or invasive coronary angiog-
raphy in conjunction with CMR results. If patients
were found to have a small area of LGE in an
ischemic distribution that was thought not to be
signiﬁcant enough to cause the degree of left ven-
tricular systolic impairment seen they were classiﬁed
as DCM; conversely, in some patients, there was a
deﬁnite regional wall motion abnormality in
conjunction with a history of signiﬁcant stenosis on
invasive or CT coronary angiography (>70%), and
we recorded these patients as having ICM. We
excluded all patients referred for a secondary pre-
vention ICD and those with renal impairment
(estimated glomerular ﬁltration rate <30 ml/min/
1.73 m2). The West of Scotland Research Ethics
Committee approved the study.
CMR protocol. All patients underwent a clinically
indicated CMR examination with a 1.5-T scanner
(Avanto Siemens, Erlangen, Germany). The pro-
tocols, imaging sequences, and analysis have been
previously described (15). Brieﬂy, cine images were
obtained using a steady-state free precession sequence
in 3 long-axis planes (2-, 3-, and 4-chamber) and in
short-axis slices through the left ventricle (echo time/
repetition time/ﬂip angle 1.4/3.5/50; spatial resolu-
tion 1.7 2mm; slice thickness 8mm).LGE imaging
for myocardial infarction was acquired 10min (after a
total accumulative gadolinium–diethylene triamine
pentaacetic acid of 0.15 mmol/kg) by an inversion
recovery fast gradient echo sequence. Inversion time
was adjusted to null normal myocardiumdtypically
this was between 280 and 320 ms. CMR was carried
out within a mean of 3  1 days of deﬁbrillator
insertion.
All analyses were performed using commercially
available proprietary software (Argus, Siemens).
Left ventricular diameter, volumes, and function
were derived from the short-axis slices using manual
tracing of the endocardial contours, including
papillary muscles as part of the ventricular volume.
The presence of LGE was assessed by identiﬁcation
of areas ofmyocardiumwitha signal intensity of>5SD
above normal myocardium. Quantiﬁcation of LGE
was measured using manual planimetry in short axis
and taking this area as a percentage of the total left
ventricular area measured in short axis.
NT-proBNP sampling. Serum NT-proBNP was
obtained within 2  1 weeks of deﬁbrillator im-
plantation and analyzed in our local laboratory,
the methods for which have been previously des-
cribed (16). Blood samples were collected in
ethylenediamine–tetraacetic acid–containing tubes
before being centrifuged at 3,000 rpm for 10 min at
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5630C before measurement of NT-proBNP using a
chemiluminescent immunoassay kit (Roche Diag-
nostics, Basel, Switzerland) on an Elecsys 2010
analyzer (Roche Diagnostics). Normal values in our
laboratory are <125 pg/ml in patients <75 years of
age and <450 pg/ml in patients >75 years of age.
All participants were stable outpatients, and he-
modynamic status at the time of sampling was
similar to status at the time of CMR.
ICD implantation. All patients had an ICD or
CRT-D device implanted using standard tech-
niques. Choice of device was at the discretion of the
operator. Following implantation deﬁbrillation
threshold, testing was carried out in all cases to
ensure an appropriate safety margin for device
programming.
Clinical follow-up. The pre-deﬁned primary
outcome was death or appropriate ICD therapy
(either shock for ventricular ﬁbrillation/tachycardia
or antitachycardia pacing for ventricular tachycardia
[VT]). All patients were followed up at 3- to
6-month intervals using computerized record link-
age for death and admissions for ventricular arrhy-
thmias causing appropriate ICD activation. Further
information about appropriate ICD activation not
causing hospital admission was obtained by
searching the records of routine local hospital ICD
interrogations. The interrogations occur every 6
months unless the patient experiences a potential
ICD activation, in which case the ICD is interro-
gated after a patient reports the potential event. An
independent observer blinded to the CMR analysis
and NT-proBNP results adjudicated events (N.T.).
No patients were lost to follow-up.
Statistical analysis. Continuous variables are
expressed as mean  SD (median and interquartile
range when appropriate), and categorical variables
are expressed as n (%). Differences between groups
were tested using Student t tests or chi-square tests
as appropriate. Because the distribution of NT-
proBNP was skewed, it was log-transformed, and
geometric means were calculated. Kaplan-Meier
and Cox proportional hazards survival analysis was
used to examine the association between LGE and
NT-proBNP (and a number of other baseline var-
iables) and the outcome of death or ICD activation.
Percentage LGE and NT-proBNP were most
strongly associated with the outcome as assessed by
the chi-square statistic and were explored further.
Due to the relatively modest number of events, the
multivariable model included only signiﬁcant uni-
variable predictors of the primary outcome (p <
0.05 in univariable Cox regression analysis). The
type of device (ICD vs. CRT-D) was also includedto try to adjust for the mortality and morbidity
beneﬁts of CRT (17). Correlation between per-
centage LGE and NT-proBNP was assessed using
the Pearson correlation coefﬁcient. Finally, to eval-
uate the optimal discriminatory level of percentage
LGE and NT-proBNP for identiﬁcation of a
population at low risk of death or ventricular
arrhythmia, we divided both DCM and ICM
groups into tertiles based on percentage LGE and
NT-proBNP. Patients with percentage LGE and
NT-proBNP in the lowest tertile for their respec-
tive group were selected as the lowest-risk cate-
gory, whereas all other patients were judged high
risk. Intraobserver and interobserver variability is as
previously described in our group (15). For all
analyses, a p value <0.05 was considered statistically
signiﬁcant, and all p values are 2-tailed. SPSS
version 19.0 was used (IBM, Armonk, New York).
RESULTS
A total of 157 patients were included, 60 with ICM
and 97 with DCM. Baseline characteristics of each
group are summarized in Table 1. Differences be-
tween the groups were as expecteddthe ICM
cohort was older with more smokers and with pa-
tients more likely to have undergone prior revascu-
larization. The ICM group was more likely to have
LGE on CMR and a higher mean volume of
ﬁbrosis measured as percentage LGE (24.8% vs.
2.1%, respectively, for ICM vs. DCM patients;
p < 0.001). The use of evidence-based therapy for
HF was high in both groups (total on beta-blockers
82.2%, angiotensin-converting enzyme inhibitors
82.2%, and spironolactone 58.9%). As would be
expected, the majority of patients had mild to
moderately symptomatic HF (86.6% NYHA func-
tional class II to III) and low ejection fraction by
CMR.
Median follow-up for patients without the pri-
mary outcome was 915 days. During the follow-up
period, 32 patients (20.4%) died or had appro-
priate ICD therapy (either shock for ventricular
ﬁbrillation/tachycardia or antitachycardia pacing
for sustained VT). There were 12 cardiac deaths
(10 due to end-stage HF and 2 due to myocardial
infarction), 14 appropriate deﬁbrillator shocks, and
6 episodes of appropriate antitachycardia pacing.
The differences between the groups stratiﬁed by
outcome are summarized in Table 2. Patients who
experienced the primary outcome were more likely
to have ICM and LGE on CMR and overall had
a higher mean percentage LGE (18.8% vs. 7.4%;
p ¼ 0.01). The patients who experienced the
Table 1. Baseline Clinical and CMR Characteristics of the Cohort Stratiﬁed
by Etiology
Dilated
Cardiomyopathy
(n [ 96)
Ischemic
Cardiomyopathy
(n [ 61) p Value
Clinical
Age, yrs 46.0  13.4 57.7  11.2 <0.001
Male 75 (78.1) 48 (78.6) 0.69
AF 18 (18.8) 17 (27.9) 0.15
Hypertension 14 (14.6) 13 (21.3) 0.24
Smoker 19 (19.8) 23 (37.7) 0.010
Diabetes 6 (6.3) 8 (13.1) 0.13
Prior revascularization 6 (6.3) 32 (52.5) <0.001
LBBB 32 (33.3) 19 (31.1) 0.86
NYHA functional class
I 15 (15.6) 0 (0.0) 0.006
II 38 (39.6) 24 (39.3)
III 38 (39.6) 36 (59.0)
IV 5 (5.2) 1 (1.6)
Medications
ACEI/ARB 75 (78.1) 54 (88.5) 0.044
Beta-blocker 79 (86.8) 50 (82.0) 0.76
Spironolactone 46 (47.9) 46 (75.4) <0.001
Furosemide 52 (54.2) 45 (73.8) 0.007
Digoxin 13 (13.5) 6 (9.8) 0.52
Investigations
ln NT-proBNP 7.06  1.24 7.46  1.05 0.018
Median NT-proBNP, pg/ml 1,568.0 (363.0–2,760.5) 2,023.0 (576.0–4,779.0) 0.09
CMR variables
LGE present 24 (25) 61 (100) <0.001
LGE, % 2.1  6.0 24.8  16.2 <0.001
CMR LV end-diastolic
diameter, cm
6.9  2.0 6.7  1.5 0.65
CMR LVEF, % 27.2  16.3 28.5  12.9 0.71
Values are mean  SD, n (%), or median (interquartile range).
ACEI ¼ angiotensin-converting enzyme inhibitor; AF ¼ atrial ﬁbrillation; ARB ¼ angiotensin receptor
blocker; CMR ¼ cardiac magnetic resonance; LBBB ¼ left bundle branch block; LGE ¼ late gadolinium
enhancement; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; NT-proBNP ¼ N-terminal pro–
B-type natriuretic peptide; NYHA ¼ New York Heart Association.
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564primary outcome also had a higher median NT-
proBNP level (4,153 pg/ml vs. 1,568 pg/ml; p ¼
0.012).
Patient characteristics associated with the pri-
mary outcome in a univariable analysis are sum-
marized in Table 3. The primary outcome occurred
in 7 patients with no LGEdthere were 3 deaths
due to end-stage HF and 4 episodes of appropriate
ICD activation. Ischemic etiology (hazard ratio
[HR]: 2.42; 95% conﬁdence interval [CI]: 1.19 to
4.9; p ¼ 0.015), presence of LGE (HR: 3.77; 95%
CI: 1.48 to 9.58; p ¼ 0.005), and percentage LGE(HR per 1% increase: 1.05; 95% CI: 1.02 to 1.07;
p < 0.001) were all associated with the primary
outcome. ln NT-proBNP was also a signiﬁcant
predictor of the primary outcome (HR: 1.71; 95%
CI: 1.22 to 2.39; p ¼ 0.002). Percentage LGE, ln
NT-proBNP, and etiology of cardiomyopathy
(ICM or DCM) were entered into the multivari-
able model, with adjustment for device type (ICD
or CRT-D). Both percentage LGE (HR: 1.04;
95% CI: 1.02 to 1.07; p ¼ 0.001) and ln NT-
proBNP (HR: 1.69; 95% CI: 1.15 to 2.47;
p ¼ 0.007) remained signiﬁcant predictors of the
primary outcome (Table 4).
There was no signiﬁcant correlation between
LGE and ln NT-proBNP (Pearson correlation
coefﬁcient 0.14; p ¼ 0.22). Based on the combi-
nation of percentage LGE and NT-proBNP, we
were able to stratify the cohort into 2 groups as
follows: low risk (DCM: n ¼ 20, LGE 0%, NT-
proBNP <545 pg/m; ICM: n ¼ 11, LGE <23%,
NT-proBNP <898 pg/ml) and high risk (DCM:
n ¼ 76, LGE >0%, NT-proBNP $545 pg/ml;
ICM: n ¼ 50, LGE $23%, NT-proBNP $898
pg/ml) (Table 5). There was no signiﬁcant differ-
ence in etiology in the composition of the 2 groups
(p ¼ 0.67). The primary outcome occurred in 1 of
the patients (3%) in the low-risk group, giving an
event rate of 1.5% per year, in comparison with
the primary outcome occurring in 31 (24.6%) of the
high-risk group (event rate 12.3% per year)
(Table 5). With the low-risk group as the reference,
patients in the high-risk group had a higher risk of
death or appropriate ICD activation (high-risk
group HR: 9.12; 95% CI: 1.24 to 66.82; p ¼ 0.03)
(Table 5 and Fig. 1A). This trend remained
consistent when the cohort was broken down
into individual etiologies (p ¼ 0.008) (Online
Fig. 1).
Secondary outcome: appropriate ICD activation.
Appropriate ICD shock or antitachycardia pacing
for VT occurred in 20 patients. Both percentage
LGE (HR: 1.04; 95% CI: 1.01 to 1.07; p ¼ 0.004)
and ln NT-proBNP (HR: 1.81; 95% CI: 1.09 to
3.03; p ¼ 0.023) remained multivariable predictors
of outcome (Table 4). Patients not in the low-risk
group had a higher risk of the appropriate ICD
activation (Fig. 1B). Again, the high-risk group
had poorer survival when the etiologies were
separated (p ¼ 0.018) (Online Fig. 2). Only 1
patient in the low-risk group had an appropriate
ICD activation over the follow-up period, an
event rate of 1% per year, in comparison with the
high-risk group, who had an event rate of 10.1%
per year.
Table 2. Clinical and CMR Characteristics Stratiﬁed According to Occurrence
of the Primary Outcome (Death or Appropriate ICD Activation)
Primary Outcome
(n [ 32)
Without Primary
Outcome
(n [ 125) p Value
Clinical
Age, yrs 51.6  16.8 50.2  13.2 0.64
Male 27 (84.4) 96 (76.8) 0.35
ICM 18 (56.2) 43 (34.4) 0.024
Diabetes 5 (16.7) 9 (7.1) 0.058
LBBB 8 (26.7) 43 (33.9) 0.84
NYHA functional class
I 1 (3.1) 14 (11.2) 0.11
II 19 (59.4) 43 (34.4)
III 11 (34.4) 63 (50.4)
IV 1 (3.1) 5 (4.0)
Medications
ACEI/ARB 18 (60.0) 111 (87.4) 0.059
Beta-blocker 18 (60.0) 111 (87.4) 0.001
Spironolactone 13 (43.3) 79 (62.2) 0.33
Investigations
ln NT-proBNP 7.79  1.09 7.02  1.19 0.005
NT-proBNP, pg/ml 4,153.0 (1,116.5–5,943.0) 1,568.0 (494.0–2,864.0) 0.012
CMR variables
Presence of LGE 19 (59.3) 53 (42.4) 0.015
LGE, % 18.8  17.7 7.4  13.4 0.01
CMR LVEF, % 26.2  12.8 27.9  12.8 0.67
Values are mean  SD, n (%), or median (interquartile range).
ICD ¼ implantable cardioverter-deﬁbrillator; ICM ¼ ischemic cardiomyopathy; other abbreviations
as in Table 1.
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565DISCUSS ION
In one of the largest studies to date of patients
undergoing implantation of an ICD or CRT-D, we
found a number of important associations with
death or appropriate use of the deﬁbrillators. LGE
and NT-proBNP can be used to predict adverse
cardiac outcomes in patients with ICDs. The
increasing burden of myocardial ﬁbrosis (scar) as
measured by percentage LGE was associated with
death or appropriate ICD activation independent
of etiology of HF (ICM or DCM). Finally, our
study is the ﬁrst to show that in primary prevention
patients, the volume of LGE and NT-proBNP can
be combined to provide incremental information on
risk stratiﬁcation, identifying a population at sig-
niﬁcantly increased risk of adverse cardiovascular
outcome and a population at lower risk of adverse
outcome in whom ICD implantation may not be
mandatory.
The presence of LGE on CMR identiﬁes areas
of myocardial scar and ﬁbrosis. The link between
the pathological presence of scar and ﬁbrosis and
ventricular arrhythmias leading to sudden death
is well established, caused by the presence of an
arrhythmogenic substrate (5,18). Several recent
studies have identiﬁed the utility of LGE to
predict ICD activation in both ICM (9,19–21)
and DCM (10). Our study not only corrobo-
rated the preceding evidence that the presence of
LGE confers an increased risk of adverse
outcome but further adds that risk increases in
proportion with the volume of LGE and that this
is more important than the presence of LGE
alone. Two small studies have reported that scar
size is associated with adverse outcome in pa-
tients with ICM (9,21). Gao et al. (6) studied
124 patients with ICM and DCM and reported
that LGE mass was the most signiﬁcant univar-
iate predictor of the primary combined outcome
(ICD activation, sudden death, or survived car-
diac arrest), although they did not test this in a
multivariable model. We have demonstrated in a
larger cohort that this association persists after
adjustment for the etiology of the cardiomyopa-
thy and NT-proBNP, which is a consistently
strong marker of prognosis in HF (22). A small
retrospective study by Scott et al. (9) also
described a similar relationship in 64 patients
with ICM.
NT-proBNP is secreted by the ventricles in
response to increased cardiomyocyte stretch caused
by pressure and volume overload (22). It has been
shown to be useful as both a diagnostic and aprognostic marker in HF (23–25). Several studies
have also examined its utility in predicting adverse
outcomes in patients with ICDs. A meta-analysis by
Scott et al. (26) identiﬁed 8 studies (enrolling a total
of 1,047 patients) and found that NT-proBNP (or
BNP) levels above the study median increased risk
of occurrence of death or ventricular arrhythmia in
those with or without an ICD. Another large
study by Verma et al. (27) evaluated 345 consecutive
patients undergoing primary or secondary preven-
tion ICD implantation and found that BNP was the
only signiﬁcant multivariable predictor of death or
appropriate ICD activation. Finally, in a large Ital-
ian multicenter study, Biasucci et al. (13) evaluated
300 patients with ICM undergoing primary pre-
vention ICD implantation. In this study, the re-
searchers’ primary hypothesis was the use of
C-reactive protein as a marker of risk; however, they
also found that NT-proBNP levels above the me-
dian was a signiﬁcant predictor of sudden cardiac
Table 4. Multivariab
ICD Activation
LGE, per 1% increase
Log NT-proBNP
ICM
*Adjusted for device type
Abbreviations as in Table
Table 3. HR and 95% CI for the Association Between Clinical and CMR
Characteristics and Death or ICD Activation
Death/Appropriate ICD
Activation (n [ 32)
Appropriate ICD
Activation (n [ 20)
Univariable
HR* (95% CI) p Value
Univariable
HR* (95% CI) p Value
Clinical
Age 1.02 (0.99–1.04) 0.26 1.02 (0.99–1.05) 0.21
Male 1.27 (0.48–3.37) 0.64 0.79 (0.25–2.52) 0.70
ICM 2.42 (1.19–4.90) 0.015 2.63 (1.07–6.50) 0.035
Diabetes 2.14 (0.82–5.58) 0.12 2.75 (0.91–8.29) 0.07
LBBB 1.46 (0.64–3.31) 0.37 1.98 (0.72–5.45) 0.19
NYHA functional class III–IV 2.33 (0.92–5.93) 0.08 3.03 (0.82–11.17) 0.10
Medications
ACEI/ARB 0.82 (0.36–1.87) 0.64 1.58 (0.47–5.28) 0.46
Beta-blocker 0.53 (0.25–1.13) 0.10 0.66 (0.24–1.82) 0.42
Spironolactone 1.06 (0.51–2.20) 0.87 2.97 (1.01–8.72) 0.047
Investigations
ln NT-proBNP 1.71 (1.22–2.39) 0.002 1.84 (1.17–2.88) 0.008
CMR variables
Presence of LGE 3.77 (1.48–9.58) 0.005 3.30 (1.05–10.42) 0.042
LGE, per 1% increase 1.05 (1.02–1.07) <0.001 1.05 (1.02–1.08) 0.002
CMR LVEF, % 1.00 (0.97–1.03) 0.73 1.01 (0.98–1.05) 0.50
*Adjusted for device type (ICD or cardiac resynchronization therapy [device with] deﬁbrillator).
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.
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566death and ventricular arrhythmias. Nevertheless, the
combined use of NT-proBNP and percentage LGE
has not been prospectively evaluated in 1 cohort
before.
We hypothesized that because percentage LGE
and NT-proBNP are markers of different patho-
logical processes in this group, they may have a
differential association with death or ICD activa-
tion. We found that they were both strong pre-
dictors of risk in this group of patients and that
their combination provided additional prognosticle Analysis for the Prediction of Death or Appropriate
Death/Appropriate ICD
Activation (n [ 32)
Appropriate ICD
Activation (n [ 20)
Multivariable
HR* (95% CI) p Value
Multivariable
HR* (95% CI) p Value
1.04 (1.01–1.07) 0.001 1.04 (1.01–1.07) 0.004
1.69 (1.15–2.47) 0.007 1.81 (1.09–3.03) 0.023
1.01 (0.32–3.16) 0.99 1.39 (0.33–5.89) 0.66
(ICD or cardiac resynchronization therapy [device with] deﬁbrillator).
s 1 and 2.information. To the best of our knowledge, this is
the ﬁrst study to demonstrate that both markers
were able to identify a group of patients at higher
risk of adverse outcomes and that the association
was present in a cohort of patients with ICM and
DCM. Perhaps of more clinical relevance, the 2 can
also be combined to identify a group of patients at
low risk of events who might not beneﬁt from ICD
implantation. This may be important given the so-
cial and psychological implications of a deﬁbrillator
and an estimated complication incidence of 4% (28).
Several studies have evaluated the prognostic
value of LGE and NT-proBNP individually.
Recently, a study by Wu et al. (29) demonstrated
the incremental prognostic utility of a combination
of imaging and biomarker in patients with chronic
HF for prediction of death and arrhythmic events.
In this study, the researchers found that the com-
bination of LGE and C-reactive protein was able
to identify a cohort at very low risk of adverse
cardiovascular outcome. Interestingly, the resear-
chers also noted that patients with the primary
outcome had higher NT-proBNP levels, although
they did not explore this further. We have de-
monstrated for the ﬁrst time that even after
adjustment for the presence of each other, per-
centage LGE and NT-proBNP levels were still
associated with adverse outcomes. This is particu-
larly important given the wider availability of serum
NT-proBNP testing and its ease of use and
interpretation compared with CMR, which is a
more specialized tool. Importantly, the primary
outcome occurred in 11 patients without LGE,
37% of the total number. Therefore, although LGE
appears to be an important predictor of adverse
outcome, this ﬁnding highlights the value of a
multimarker model of risk. Furthermore, it may be
of beneﬁt in patients unable to undergo CMR, for
example in those with contrast allergy or renal
impairment. Of course, in centers with access to
CMR, the combination of these 2 markers provides
even more predictive conﬁdence. There may also be
advantages to identifying a group of lower-risk
patients in which the clinician is unsure of pro-
ceeding to ICD insertion, perhaps for example in
those with ejection fractions around 35% and in
NYHA functional class I/II. Ejection fraction can
ﬂuctuate over time, whereas NYHA functional
class can be fairly subjective. These factors may
account for some of the current reduced cost
effectiveness of ICDs. There is an increasing
recognition, however, that risk stratiﬁcation for
ICD implantation may be further reﬁned by using
other markers such as LGE and NT-proBNP;
Table 5. Association Between Optimal Discriminatory Level of LGE and NT-proBNP and Death or ICD Activation
Group Etiology LGE, %
NT-proBNP
(pg/ml)
Number of
Patients
Death/Appropriate ICD
Activation (%)
Appropriate ICD
Activation
Low risk DCM
ICM
0
<23
<545
<898
20 (20.8)
11 (18.0)
1 (3.1) 0 (0.0)
High risk DCM
ICM
>0
$23
$545
$898
76 (79.2)
50 (82.0)
31 (24.6)* 20 (15.9)*
*p < 0.05 compared with low-risk group.
Abbreviations as in Tables 1 and 2.
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567hence, more studies of this type are required to
optimize patient selection and improve outcomes.
Study limitations. Although our sample size and
number of events were relatively small and the study
was conducted in a single center, our cohort of 157
patients is one of the largest to date of patients
undergoing primary prevention deﬁbrillator im-
plantation, CMR examination, and measurement of
NT-proBNP. Nevertheless, a larger multicenter
study is needed to validate our ﬁndings. The overall
death rate in our cohort (8.3%) was lower than that
reported in the MADIT-II (Multicenter Automatic
Deﬁbrillator Implantation Trial II) study (14.2%
in 20 months), whereas our rate of appropriate
ICD therapies was also lower than that in largerFigure 1. Survival Curves for the Population
Kaplan-Meier curves of the association between the combination of late
peptide (NT-proBNP) for prediction of death or appropriate implantable c
ICD activation alone. (B) Stratiﬁed into 2 risk groups: dilated cardiomyo
NT-proBNP $545 pg/ml) and ischemic cardiomyopathy (low-risk LGE <
$848 pg/ml).multicenter trials (1,30). Larger studies are needed
to ﬁnd the optimal cutoff points for these markers to
be used as risk stratiﬁers to avoid ICD implantation.
These would also allow the incorporation of other
variables that may be clinically important.
We used a threshold of >5 SD between remote
myocardium and ﬁbrosed myocardium, rather than
other methods such as >2 SD or the “full width-
half-max” (FWHM) method. A level of >5 SD has
been shown to be more accurate than 2 SD and as
accurate as FWHM for quantiﬁcation of ﬁbrosis by
LGE (31). Quantiﬁcation of LGE using manual
planimetry may be a potential limitation of the
study, and future techniques such as T1 mapping
may overcome this.gadolinium enhancement (LGE) and N-terminal pro–B-type natriuretic
ardioverter-deﬁbrillator (ICD) activation. (A) Prediction of appropriate
pathy (low-risk LGE 0%, NT-proBNP <545 pg/ml; high-risk LGE >0%,
23%, NT-proBNP <848 pg/ml; high-risk LGE $23%, NT-proBNP
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568CONCLUS IONS
In a real world population of patients with ICM and
DCM, both percentage of LGE and NT-proBNP
were associated with poorer outcome and used in
combination were able to discriminate risk of death
or ICD activation in patients undergoing implan-
tation of a primary prevention ICD. The use of
both markers allowed identiﬁcation of a group at
low risk for future adverse events in whom ICDimplantation may be deferred. Larger studies should
be conducted to identify the optimal levels of LGE
and NT-proBNP for these markers to be incorpo-
rated into clinical guidelines.
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